Background Tacrolimus is a key drug in kidney transplantation with a narrow therapeutic
index. However, whether tacrolimus exposure variability affects clinical outcomes and …

It is currently not clear whether the concentration‐time curves of the immunosuppressants
differ with respect to the CYP3A5, MDR1, or MRP2 genotype in dose‐adapted stable kidney …

Background This study investigated pharmacokinetic and pharmacogenetic differences
between a modified-release once-daily formulation of tacrolimus (Tac-QD) and the original …

Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

On April 22, 1997, the Food and Drug Administration (FDA) approved Prograf (tacrolimus,
Fujisawa, Inc., Deerfield, IL) for use in the prevention of graft rejection in kidney …

Background CYP3A5 gene polymorphism rs776746 has been associated with lower
tacrolimus dose requirements and bioavailability in both adults and children. This variant …

Optimal blood levels of tacrolimus in transplant recipients are critically important to preserve
the allograft. Suboptimal doses of the immunosuppressant can result in allograft toxicity or …

Background: Kidney transplant recipients with high intrapatient variability (IPV) in tacrolimus
(Tac) exposure experience more rejection and reduced graft survival. To understand the …

Aim As a substrate of cytochrome P450 (CYP) 3A5, tacrolimus is characterised by a narrow
therapeutic index and large inter‐individual variability. Our objective was to determine the …

Purpose The aim of this study was to evaluate the effect of different clinical covariates on
tacrolimus dose requirements in adult kidney transplant patients with a specific focus on …